QURE
Price:
$17.35
Market Cap:
$845.69M
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzhe...[Read more]
Industry
Biotechnology
IPO Date
2014-02-05
Stock Exchange
NASDAQ
Ticker
QURE
According to uniQure N.V.’s latest financial reports and current stock price. The company's current Enterprise Value is 661.66M. This represents a change of 104.93% compared to the average of 322.87M of the last 4 quarters.
The mean historical Enterprise Value of uniQure N.V. over the last ten years is 734.06M. The current 661.66M Enterprise Value has changed 8.91% with respect to the historical average. Over the past ten years (40 quarters), QURE's Enterprise Value was at its highest in in the June 2019 quarter at 2.79B. The Enterprise Value was at its lowest in in the June 2016 quarter at 21.70M.
Average
734.06M
Median
461.33M
Minimum
27.94M
Maximum
2.56B
Discovering the peaks and valleys of uniQure N.V. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.29%
Maximum Annual Enterprise Value = 2.56B
Minimum Annual Increase = -82.92%
Minimum Annual Enterprise Value = 27.94M
Year | Enterprise Value | Change |
---|---|---|
2023 | 219.78M | -77.44% |
2022 | 974.36M | 82.73% |
2021 | 533.23M | -62.79% |
2020 | 1.43B | -44.05% |
2019 | 2.56B | 209.48% |
2018 | 827.71M | 112.55% |
2017 | 389.42M | 1.29% |
2016 | 27.94M | -82.92% |
2015 | 163.56M | -22.04% |
2014 | 209.80M | -10.86% |
The current Enterprise Value of uniQure N.V. (QURE) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
575.79M
5-year avg
1.14B
10-year avg
734.06M
uniQure N.V.’s Enterprise Value is less than Rocket Pharmaceuticals, Inc. (1.20B), less than Rhythm Pharmaceuticals, Inc. (3.39B), greater than Solid Biosciences Inc. (127.34M), greater than MeiraGTx Holdings plc (446.07M), greater than Terns Pharmaceuticals, Inc. (223.81M), greater than Amylyx Pharmaceuticals, Inc. (204.92M), greater than Acumen Pharmaceuticals, Inc. (104.35M), greater than Inozyme Pharma, Inc. (210.44M), greater than X4 Pharmaceuticals, Inc. (79.71M), less than Vaxcyte, Inc. (9.69B), greater than Larimar Therapeutics, Inc. (211.48M), less than Syndax Pharmaceuticals, Inc. (983.46M), less than Merus N.V. (2.47B), greater than Sutro Biopharma, Inc. (9.43M), less than Kiniksa Pharmaceuticals, Ltd. (1.35B), less than Day One Biopharmaceuticals, Inc. (857.57M), less than Structure Therapeutics Inc. (1.45B), less than Karuna Therapeutics, Inc. (12.43B), greater than Phathom Pharmaceuticals, Inc. (354.56M), greater than REGENXBIO Inc. (394.08M), less than Replimune Group, Inc. (904.39M), less than Avidity Biosciences, Inc. (3.38B), less than Protagonist Therapeutics, Inc. (2.22B),
Company | Enterprise Value | Market cap |
---|---|---|
1.20B | $1.24B | |
3.39B | $3.43B | |
127.34M | $167.01M | |
446.07M | $482.21M | |
223.81M | $492.65M | |
204.92M | $274.19M | |
104.35M | $107.54M | |
210.44M | $188.22M | |
79.71M | $98.92M | |
9.69B | $10.71B | |
211.48M | $241.19M | |
983.46M | $1.12B | |
2.47B | $2.90B | |
9.43M | $159.15M | |
1.35B | $1.44B | |
857.57M | $1.28B | |
1.45B | $1.62B | |
12.43B | $12.60B | |
354.56M | $512.83M | |
394.08M | $366.63M | |
904.39M | $941.76M | |
3.38B | $3.74B | |
2.22B | $2.34B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like uniQure N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like uniQure N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is uniQure N.V.'s Enterprise Value?
What is the highest Enterprise Value for uniQure N.V. (QURE)?
What is the 3-year average Enterprise Value for uniQure N.V. (QURE)?
What is the 5-year average Enterprise Value for uniQure N.V. (QURE)?
How does the current Enterprise Value for uniQure N.V. (QURE) compare to its historical average?